President Trump Signed Executive Order on Psychedelic Research
The directive aims to accelerate federal research into the therapeutic potential of psychedelic drugs for mental health.
Updated on Oct. 14, 2026 in Substance Abuse
Live Poll
Should federal research prioritize the development of psychedelic drugs for treating severe mental health conditions?
President Donald Trump has signed an executive order to prioritize and accelerate federal research regarding the medical use of psychedelic drugs. This shift comes as the FDA reviews three separate psychedelic treatments for potential use in addressing depression and PTSD.
Why it matters
The executive order seeks to expedite scientific understanding of these substances to treat severe mental health conditions. While most psychedelics remain federally prohibited, this move could lead to wider clinical implementation.
Three psychedelic drugs are currently undergoing expedited FDA review for mental health conditions. Research studies indicate that ketamine treatments typically require a six-week duration for patient transformation.
The players
President Donald Trump
President Donald Trump is the current President of the United States who signed the directive to prioritize federal research on psychedelic therapeutics.
Food and Drug Administration
The Food and Drug Administration is the federal agency tasked with evaluating and fast-tracking the approval process for new medical treatments.
The details
Ketamine is currently the only legal psychedelic medicine available in North Carolina, where it is administered via IV in clinical settings. Unlike ketamine, which is used in one-hour sessions, substances like ibogaine are utilized in single, intense all-day sessions but carry significant heart risks.
Timeline
President Donald Trump signed the executive order on October 14, 2026.
FDA approvals for certain psychedelic drugs could occur later this year.
Health Landscape
This directive challenges the restrictive status of the current federal classification of psychedelic substances, which has historically limited scientific inquiry. The move aligns with emerging state-level programs in places like Oregon and Colorado that have already legalized certain psychedelic therapies.
Patients struggling with mental health conditions may soon have access to new, FDA-approved treatment options as research accelerates. Individuals interested in these therapies should note that current access is strictly regulated and limited to specific clinical settings where legally permitted.
The takeaway
While federal research is accelerating, patients should consult with medical professionals to understand the current legal landscape and risks associated with these substances. Understanding that treatments like ketamine require ongoing supervision is essential for those seeking new therapeutic avenues.
Further reading
Find more information on current regulations at Substance Abuse.
Source note: This article includes information reported by Investigatetv.
Live Poll
Should federal research prioritize the development of psychedelic drugs for treating severe mental health conditions?
